Are 'great' tweet­ers born? Or can they be made? A con­ver­sa­tion with Adam Feuer­stein.


If you’re a drug de­vel­op­ment pro­fes­sion­al with am­bi­tion, you can’t af­ford to ig­nore Twit­ter. No mat­ter your opin­ion of Twit­ter as a com­pa­ny, the act of tweet­ing is here to say: short, pub­lic, one-to-many com­mu­ni­ca­tion is nev­er be­ing put back in the bot­tle. I’ve writ­ten about this is­sue be­fore, of­fer­ing a list of 300 ac­counts known to tweet bio­phar­ma-re­lat­ed news fastest. Main­tain­ing a good list of fol­lowed ac­counts, con­sum­ing your news di­rect­ly from the source, ex­pos­ing your­self to a di­ver­si­ty of opin­ion out­side your com­fort zone: that’s BioTwit­ter 101, the min­i­mum re­la­tion­ship a drug de­vel­op­er ought to have with so­cial me­dia. There’s no ex­cuse to dis­miss all so­cial me­dia with a wide brush of this doesn’t ap­ply to me. You don’t have to tweet to be good at Twit­ter.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.